Get the Stockscreener App
17.34
0.81%
0.14
Immunome Inc stock is traded at $17.34, with a volume of 404.17K.
It is up +0.81% in the last 24 hours and down -27.60% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$17.20
Open:
$17.31
24h Volume:
404.17K
Relative Volume:
0.28
Market Cap:
$2.05B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-7.2872
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
-10.20%
1M Performance:
-27.60%
6M Performance:
-25.87%
1Y Performance:
+6.06%
1-Day Range:
$17.08
$17.61
1-Week Range:
$17.13
$19.73
52-Week Range:
$13.53
$30.06
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
17.34 | 2.05B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Initiated | Stifel | Hold |
| Sep-21-26 | Initiated | Alliance Global Partners | Buy |
| May-28-26 | Initiated | Barclays | Overweight |
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome stock holds at Stifel as Bristol deal cleans up license - Investing.com
ImmunomeEnters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026 - TradingView
Immunome stock gets FDA clearance for fifth clinical program - AD HOC NEWS
Immunome, Inc. (IMNM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Yahoo Finance
IMNM Initiated Coverage by Stifel -- Rated Hold with PT at $24.0 - gurufocus.com
Stifel Initiates Immunome at Hold With $24 Price Target - Yahoo Finance
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues - Yahoo Finance
Immunome gains FDA IND clearance for IM‑1340 solid tumour study - Mugglehead Investment Magazine
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com Nigeria
Stifel initiates Immunome stock coverage with Hold rating at $24 - Investing.com
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com South Africa
Immunome (IMNM) Gains FDA IND Clearance for IM-1340 Targeting Ad - gurufocus.com
Immunome receives FDA clearance for IM-1340 solid tumor trial - Investing.com
Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com - Investing.com South Africa
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
(IMNM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32 - Moomoo
IMNM Initiates Coverage On Alliance Global Partners -- Rating Se - GuruFocus
Immunome (Nasdaq:IMNM)Stock Analysis - Simply Wall Street
Immunome Stock Price Forecast. Should You Buy IMNM? - StockInvest.us
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Immunome CSO Higgins Jack Executes 18,000 Options at $1.35, Sells and Gifts Shares (NASDAQ: IMNM) - Kalkine Media
Immunome Inc. (IMNM) Edges Up 2.51% to $24.55 as Buyers Hold Above Key SupportPCR Spike - careplusvn.com
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice - Stock Titan
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateSmart Beta Flow - vinanet.vn
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - simplywall.st
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Sep 11 '26 |
Sale |
25.32 |
13,200 |
334,224 |
65,050 |
| Higgins Jack | Officer |
Sep 11 '26 |
Proposed Sale |
25.32 |
13,200 |
334,224 |
0 |
| Barchas Isaac | Director |
Aug 12 '26 |
Proposed Sale |
27.25 |
11,048 |
301,058 |
0 |
| Barchas Isaac | Director |
Aug 12 '26 |
Sale |
27.25 |
11,048 |
301,058 |
92,211 |
| Barchas Isaac | Director |
Aug 11 '26 |
Sale |
26.23 |
62,291 |
1,633,893 |
0 |
| Barchas Isaac | Director |
Aug 10 '26 |
Sale |
26.07 |
10,125 |
263,959 |
62,291 |
| Barchas Isaac | Director |
Aug 07 '26 |
Sale |
26.06 |
15,248 |
397,363 |
72,416 |
| Barchas Isaac | Director |
Aug 06 '26 |
Sale |
26.06 |
20,840 |
543,090 |
87,664 |
| ABHMC II, LLC | Shareholder |
Aug 06 '26 |
Proposed Sale |
25.52 |
108,504 |
2,769,022 |
0 |
| Horn Kinney | CHIEF BUSINESS OFFICER |
Aug 04 '26 |
Sale |
25.09 |
90,616 |
2,273,555 |
0 |
6.08%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):